一、中文文獻
內政部,2010年,人口政策資料彙集。
世界衛生組織(1998年),基本條款清單,健康促進詞彙,2009年5月1日取從
http://www.who.int/hpr/NPH/docs/hp_glossary_en.pdf
台灣腦中風防治指引2008.
http://www.stroke.org.tw/guideline/guideline_new.asp2008 [cited 2012 May 8]
吳美芳、劉雪娥(2007)‧腦中風病患發病時的自我覺查與尋求醫療處置方式之探
討‧長庚護理,18(2),177-187‧
行政院衛生署(2011).2011年全國主要十大死因統計,取自
http://www.doh.gov.tw/CHT2006/DM/DM2_p01.aspx?class_no=25&;level_no=
1&;doc_no=84788‧
邱珍琬(2002).自我察覺扎記在諮商師養成教育中的運用及實際.輔導季刊38(3),66-74‧余季芹、胡瑞桃、葉集孝(2008).冠狀動脈繞道手術後病患之自我效能、社會支
持與自我照顧行為之相關探討.長庚護理,19(1),41-52‧
林靜薇、蕭世美(2010).血栓溶解劑治療急性缺血性腦中風病人之護理.榮總護
理,27(4),382-387‧
胡漢華(2008).台灣腦中風防治指引.台北:台灣腦中風學會.
美國心臟醫學會/美國腦中風醫學會官方網站。
http://www.strokeassociation.org/STROKEORG/。上網時間:2013年2月
25日。
翁文章、陸仁安、陳昌明、胡漢華、連立明、陳俊榮(2000).台灣急性缺血性腦
中風的靜脈注射血栓溶解劑治療.中華民國急救加護醫學雜誌,2,103
-111。
黃偉城、周騰達、蕭添木、黃志芳、王培銘、曾高智等(2006).腦中風居家護理
個案預後因素的探討.台灣醫誌,16(4),251-259.
陳志弘(2010).中風治療品質:談急性中風靜脈血桂溶解治療之比例.腦中風學
會會訊,17, 2-4‧
傅進華、曹汶龍(2003)‧東台灣急性腦中風病患就醫時效性分析‧慈濟醫學,15(4),241-246‧
廖建彰、李某娟、林瑞雄、宋鴻樟(2006)‧2000年台灣腦中風發生率與盛行率的
城鄉差異‧台灣公共衛生雜誌, 25,223-30‧
葉炳強、呂建榮、鄭建興(1999)‧急性腦中風的緊急處理‧當代醫學,22(6),469-473‧
顏芳慧、許敏桃(2004).初次罹患急性心肌梗塞婦女發病的生病經驗.護理雜
誌,51(2),57-65‧
二、英文文獻
Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L,
Furlan .(2007). Guidelines for the early management of adults with ischemic stroke. Circulation﹐115﹐478–534.
Billings-Gagliardi S, Mazor KM.(2005). Development and validation of
the stroke action test. Stroke﹐36﹐1035-1039.
Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton
S.(1999).Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset:The ATLANTIS Study: a randomized controlled trial.Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.JAMA﹐282﹐2019-26.
Daley S,Braimab J,Sailor S,Kongable G,Barch C,Rapp K.(1997).Ed
ucation to improve stroke awareness and emergent response.Journal of Neuroscience Nursing,29(6),393-396‧
Evans RL,Griffite J,Hase1korn JK,Hendricks RD,
Baldwin RD,Bishop DS.(1992).Poststroke family function: Anluation of the family''s role in rehabilitation.R.ehabilitation Nursing,12(3), 127-132
Feigin VL,Lawes CMM,Bennett DA.(2003). Stroke epidemiology:a review
of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurology﹐2﹐43-53.
Fonarow GC, Smith EE, Saver JL.(2011). Timeliness of tissue-type
plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors,and outcomes associated with door-to-needle times within 60 minutes.Circulation﹐123﹐750-758.
Gregg C. Fonarow, Eric E. Smith, Jeffrey L. Saver.(2011). Improvingdoor-to-needle times in acute ischemic stroke: the design and
rationale for the American Heart Association/American Stroke Association''s Target: Stroke initiative. Stroke﹐42﹐2983-9.
Hacke W,Donnan G,Fieschi C,Kaste M,Kummer R,Broderick JP.(2004).
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet﹐363﹐768–774.
Hsia AW,Castle A,Wing JJ,Edwards DF,Brown NC,Higgins TM.(2011).
Understanding reasons for delay in seeking acute stroke care in an underserved urban population. Stroke﹐42﹐1697-1701.
Hu HH,Chu FL,Chiang BN.(1989). Prevalence of stroke in Taiwan.
Stroke﹐20﹐858-63.
Hacke W,Kaste M,Fieschi C.(1995). Intravenous thrombolysis with
recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA﹐274﹐1017-1025.
Hacke W,Kaste M,Fieschi C.(1998) Randomised double-blind
placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet﹐52﹐1245-1251.
Hacke W,Donnan G,Fieschi C.(2004). Association of outcome with early
stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.Lancet﹐363﹐768-74.
Hacke W,Kaste M,Bluhmki E.(2008). Thrombolysis with alteplase 3 to
4.5 hours after acute ischemic stroke. N Engl J Med﹐359﹐1317-1329.
Hazinski MF, Nolan JP, Billi JE.(2010). Part 1: Executive Summary:
2010 International Consensus on Cardiopulmonary Resuscitation and
Emergency Cardiovascular Care Science With Treatment Recommendations.Circulation. In press.
Lansberg MG,Bluhmki E,Thijs VN.(2009). Efficacy and safety of tissue
plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke﹐40﹐2438-2441.
Lees KR,Bluhmki E,Kummer Rv.(2010). Time to treatment with
intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS,ATLANTIS, NINDS, and EPITHET trials. Lancet.﹐375﹐1695–1703.
Lees KR,Bluhmki E,Kummer Rv.(2010). Time to treatment with
intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS,ATLANTIS, NINDS, and EPITHET trials. Lancet﹐375﹐1695–703.
Lansberg MG,Bluhmki E,Thijs VN.(2009). Efficacy and safety of
tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke﹐40﹐2438-41.
Jones SP,Jenkinson AJ,Leathley MJ,Watkins CL.(2010). Stroke knowledge
and awareness: an integrative review of the evidence. Age Ageing.﹐39﹐11-22.
Pedersen PM,Jorgensen HS,Nakayama H,Raaschou HO.(1996). Orientation in the acute and chronic stroke patient: Impact on ADL and social activities. The Copenhagen Stroke Study. Archives of Physical Medicine and Rehabilitation ﹐77(4)﹐336-339.
Moser DK,Kimble LP,Alberts MJ,Alonzo A,Croft JB,Dracup K.(2006).
Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on Cardiovascular Nursing and Stroke Council. Circulation﹐114﹐168 –182.
National Institute of Neurological Disorders and Stroke rt-PA Stroke
Study Group.(1995). Tissue plasminogen activator for acute ischemic stroke.N Engl J Med﹐333﹐1581–1587.
Puolakka T,V?爨rynen T,H?鑽p?匜? O,Soinne L,Kuisma M,Lindsberg PJ.(2010).
Sequential analysis ofpretreatment delays in stroke thrombolysis. Acad Emer Med﹐17﹐965–969.
Rausch M﹐&; Turkosk B. (1999). Developing realistic treatment
standards in today''s economic c1imate: stroke survivor education.
Joumal of Advanced nursing﹐30(2)﹐329-334.
Rossnagel K,Jungeh?刜sing GJ,Nolte CH,M?刜ler-Nordhorn J,Roll S,
Wegscheider K.(2004). Out-of-hospital delays in patients with acute
stroke. Ann Emerg Med.﹐44﹐476-83.
RosamandWD,GortonRA ,HinnAR,Hohenhaus SM,Morris DL.(1998).Rapid
response to stroke symptoms:The delay in accessing stroke healthcare(DASH)study.Academic Emergency Medicine,5(10),45-510.
Schneider AT,Pancioli AM,Khoury JC,Rademacher E,Tuchfar-bar A,Miller
R. (2003).Trends in community knowledge of the warning sings and rish factors for stroke.JAMA,289(3),343-346.
Tissue plasminogen activator for acute ischemic stroke.(1995). The
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med﹐333﹐1581-7.
Teuschl Y, Brainin M.(2010). Stroke education: discrepancies among
factors influencing prehospital delay and stroke knowledge. Int J Stroke﹐5﹐187-208.
The World Health Organization MONICA Project (monitoring trends and
determinants in cardiovascular disease).(1988). a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol﹐41﹐105-114.
Winkler R,Underwood P,Fatvich B﹐James R,Gray D. (1989). A clinical
trial of self-care approach to the management of chronic headache in general practice.Science and Medicin﹐29﹐213-219.
Yip PK,Jeng JS,LU CJ.(2000). Hospital arrival time after onset of
different types of stroke in greater Taipei. J Formos Med Assoc﹐99﹐532-7.